MORBIER CLOCKS. PART II: THE TIME TRAINSEYMOUR L. A.BULLETIN OF THE NATIONAL ASSOCIATION OF WATCH AND CLOCK COLLECTORS. 1973, Vol 15, Num 8, pp 962-976Article

NEW MUSEUM AT GENEVASEYMOUR L. A.BULLETIN OF THE NATIONAL ASSOCIATION OF WATCH AND CLOCK COLLECTORS. 1973, Vol 15, Num 8, pp 1026-1027Article

Morbier Clocks. Part III: Striking TrainsSEYMOUR L. A.Bulletin of the National Association of Watch and Clock Collectors. 1974, Vol 16, Num 6, pp 566-589Article

MORBIER CLOCKSSEYMOUR L. A.BULL. NAT. ASSOC. WATCH CLOCK COLLECT. 1972, Vol 15, Num 3, pp 271-290Article

Tourism development in Newfoundland: the past revisitedSEYMOUR, L.The Canadian geographer/Le géographe canadien Toronto. 1980, Vol 24, Num 1, pp 32-39Article

Recent Legislation: It Affects YouSEYMOUR, L.Academic Therapy San Rafael, Cal. 1977, Vol 13, Num 1, pp 53-56Article

Novel anti-cancer agents in development : exciting prospects and new challengesSEYMOUR, L.Cancer treatment reviews. 1999, Vol 25, Num 5, pp 301-312, issn 0305-7372Article

Synthetic polymers with intrinsic anticancer activitySEYMOUR, L.Journal of bioactive and compatible polymers. 1991, Vol 6, Num 2, pp 178-216, issn 0883-9115Article

The specificity of recognition by isolated rat peritoneal macrophages of N-(2-hydroxypropyl) methacrylamide copolymers containing mannosamineSEYMOUR, L. W.European journal of medicinal chemistry. 1988, Vol 23, Num 4, pp 353-358, issn 0223-5234Article

Morbier Clocks| Part4: Restoration and RepairSEYMOUR, L. A.Bulletin of the National Association of Watch and Clock Collectors Columbia, Pa. 1977, Vol 19, Num 3, pp 243-269Article

Delivering gene therapySEYMOUR, L. W.Journal of drug targeting. 2002, Vol 10, Num 2, issn 1061-186X, 83 p.Serial Issue

Passive tumour targeting of soluble macromolecules and drug conjugatesSEYMOUR, L. W.Critical reviews in therapeutic drug carrier systems. 1992, Vol 9, Num 2, pp 135-187, issn 0743-4863Article

Placental and serum Levels of carotenoids in preeclampsiaPALAN, Prabhudas R; MIKHAIL, Magdy S; ROMNEY, Seymour L et al.Obstetrics and gynecology (New York. 1953). 2001, Vol 98, Num 3, pp 459-462, issn 0029-7844Article

Apoptotic changes in cervical intraepithelial neoplasiaDUTTAGUPTA, Chandralekha; BASU, Jayasri; RAY, Monika et al.Gynecologic and obstetric investigation. 2001, Vol 52, Num 1, pp 38-42, issn 0378-7346Article

A randomized phase II study of two schedules of bryostatin-1 (NSC339555) in patients with advanced malignant melanoma: A National Cancer Institute of Canada Clinical Trials Group StudyTOZER, R. G; BURDETTE-RADOUX, S; BERLANGER, K et al.Investigational new drugs. 2002, Vol 20, Num 4, pp 407-412, issn 0167-6997, 6 p.Article

Sequential α-interferon and tamoxifen : In vitro biologic effects of two growth modulatorsSEYMOUR, L; BEZWODA, W. R.International journal of oncology. 1997, Vol 10, Num 6, pp 1277-1282, issn 1019-6439Article

Positive immunostaining for platelet derived growth factor (PDGF) is an adverse prognostic factor in patients with advanced breast cancerSEYMOUR, L; BEZWODA, W. R.Breast cancer research and treatment. 1994, Vol 32, Num 2, pp 229-233, issn 0167-6806Article

Tissue platelet derived-growth factor (PDGF) predicts for shortened survival and treatment failure in advanced breast cancerSEYMOUR, L; DAJEE, D; BEZWODA, W. R et al.Breast cancer research and treatment. 1993, Vol 26, Num 3, pp 247-252, issn 0167-6806Article

Effect of natural killer cells on syngeneic bone marrow: in vitro and in vivo studies demonstrating graft failure due to NK cells in an identical twin treated by bone marrow transplantationGOSS, G. D; WITTWER, M. A; BEZWODA, W. R et al.Blood. 1985, Vol 66, Num 5, pp 1043-1046, issn 0006-4971Article

Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29LAURIE, S. A; SOLOMON, B. J; FENTON, D et al.European journal of cancer (1990). 2014, Vol 50, Num 4, pp 706-712, issn 0959-8049, 7 p.Article

RNAi-mediated knockdown of HMG CoA reductase enhances gene expression from physiologically regulated low-density lipoprotein receptor therapeutic vectors in vivoHIBBITT, O; AGKATSEV, S; OWEN, C et al.Gene therapy (Basingstoke). 2012, Vol 19, Num 4, pp 463-467, issn 0969-7128, 5 p.Article

The impact of anemia on outcome of chemoradiation for limited small-cell lung cancer : a combined analysis of studies of the National Cancer Institute of Canada Clinical Trials GroupLAURIE, S. A; DING, K; WHITEHEAD, M et al.Annals of oncology. 2007, Vol 18, Num 6, pp 1051-1055, issn 0923-7534, 5 p.Article

Randomized phase II study of two doses of gefitinib in hormone-refractory Prostate cancer: A trial of the National Cancer Institute of Canada-Clinical trials groupCANIL, C. M; MOORE, M. J; FISHER, B et al.Journal of clinical oncology. 2005, Vol 23, Num 3, pp 455-460, issn 0732-183X, 6 p.Conference Paper

A phase II study of raltitrexed ('Tomudex'*) in patients with hepatocellular carcinomaROUGIER, P; DUCREUX, M; KERR, D et al.Annals of oncology. 1997, Vol 8, Num 5, pp 500-502, issn 0923-7534Article

Comparison between immunocytochemical and polymerase chain reaction techniques for detection of oestrogen receptor and transforming growth factor β in breast cancerAMOILS, K. D; SEYMOUR, L; BEZWODA, W. R et al.British journal of cancer. 1996, Vol 73, Num 10, pp 1255-1259, issn 0007-0920Article